|By Marketwired .||
|February 4, 2014 09:30 AM EST||
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 02/04/14 -- Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company is launching a new product at the SPIE Photonics West 2014 industry exhibit in San Francisco, California from February 4-6, 2014. Photonics West is the annual flagship event for the optics and photonics industry, with 20,000 attendees expected to attend.
The Company will be introducing and demonstrating the VRS Verisante Research System, a revolutionary rapid Raman spectroscopy system designed for the scientific research community. The Aura for skin care which uses the same platform technology used in VRS was the winner of the 2013 Prism Award in the Life Sciences and Biophotonics category at last year's Photonics West conference. VRS is the world's fastest Raman spectrometer, able to acquire Raman spectra in under one second. According to Transparency Market Research, the "global spectrometry market was worth USD 10.2 billion in 2011 and is expected to reach USD 15.2 billion in 2017". Interested parties are invited to view VRS at exhibit booth #5134 in the North Hall of the Moscone Center.
"Our technology platform allows us to sell very similar products into different sales channels. In addition to skin cancer, lung cancer, etc., we can sell into the global research and industrial markets without requiring the stringent regulatory approvals required for medical devices. Our probes and ultra fast integration time make our spectrometer a unique and valuable tool not just for cancer research, but for many other applications in research and industry," said Thomas Braun, CEO of Verisante.
SPIE is an international society advancing an interdisciplinary approach to the science and application of light. SPIE Photonics West is the world's largest and most influential photonics and optics event with over 1500 companies exhibiting and 20,000 attendees.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura for skin cancer detection and the Verisante Core series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura has been approved for sale in Canada, Europe and Australia. Core has not yet been approved for sale.
Verisante Aura was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.